Virbac SA (VIRP) AI Stock Analysis

• Market Cap: €3.04B
• Dividend Yield: 0.4%
• Average Volume (3M): 5.07K
• Price to Earnings (P/E): 22.9
• Beta (1Y): 0.61
• Revenue Growth: 6.97%
• EPS Growth: -5.59%
• Country: FR
• Employees: 6,365
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 9.84
• Shares Outstanding: 8,390,660
• 10 Day Avg. Volume: 4,115
• 30 Day Avg. Volume: 5,072
• PEG Ratio: 0.89
• Price to Book (P/B): 2.54
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 19.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €379.00
• Price Target Upside: 4.70% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 73 Outperform
• Price Target: €372.00 ▲(2.76% Upside)

Virbac SA's strong financial performance is the most significant factor, supported by stable revenue and profit growth, low leverage, and solid cash flow. Technical analysis and valuation provide a balanced view, with no significant bullish or bearish signals.

Positive Factors

Negative Factors

Virbac SA Business Overview & Revenue Model

Company Description

Virbac SA is a global animal health company headquartered in France, specializing in the development, production, and marketing of a wide range of veterinary products. Established in 1964, Virbac focuses primarily on companion animals, such as dogs and cats, as well as livestock, offering pharmaceuticals, vaccines, and diagnostic products. The company operates in various sectors including parasitology, dermatology, and nutrition, aiming to improve the health and well-being of animals worldwide.

How the Company Makes Money

Virbac generates revenue primarily through the sale of its veterinary products, which include pharmaceuticals, vaccines, and nutritional supplements for both companion animals and livestock. The company operates a diversified revenue model, with key revenue streams coming from prescription products, over-the-counter medicines, and specialized dietary products. Virbac's strategic partnerships with veterinary clinics, animal health distributors, and research institutions enhance its market reach and product development capabilities. Additionally, the company invests in research and development to innovate new treatments and expand its product portfolio, which contributes significantly to its earnings. Geographic expansion into emerging markets also plays a critical role in driving revenue growth.

Virbac SA Financial Statement Overview

Summary

Virbac SA demonstrates strong financial performance with consistent revenue growth, robust profitability margins, and effective cost management. The balance sheet is stable with minimal leverage, and cash flow generation is solid, though there is room for improvement in free cash flow conversion.

Income Statement

Virbac SA demonstrates a strong income statement with consistent revenue growth over the years. Gross Profit Margin in 2024 is approximately 67.4%, reflecting efficient cost management. Net Profit Margin stands at about 10.4%, indicating a solid profitability level. EBIT Margin of 15.5% and EBITDA Margin of 20.4% showcase robust operational efficiency. Revenue grew by approximately 12.1% from 2023 to 2024, indicating a healthy upward trajectory. Overall, the company shows strong profitability and growth, with a continuous positive trend.

Balance Sheet

The balance sheet of Virbac SA is stable with a low Debt-to-Equity Ratio of 0.04, indicating minimal leverage and financial risk. Return on Equity (ROE) is approximately 13.9%, showcasing effective utilization of shareholder equity to generate profits. The Equity Ratio of 56.4% suggests a solid capital structure with a significant portion of assets financed by equity. These metrics indicate financial stability and a well-managed balance sheet with minimal debt risk.

Cash Flow

Virbac SA's cash flow statement shows solid cash generation capabilities with a Free Cash Flow Growth Rate of approximately 128.5% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is about 1.4, indicating good cash conversion. Free Cash Flow to Net Income Ratio stands at 0.93, reflecting efficient management of capital expenses. The company exhibits strong cash flow management, though a higher free cash flow conversion ratio would further enhance its cash flow position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.43B	1.40B	1.25B	1.22B	1.06B	934.20M
Gross Profit	952.21M	937.60M	809.60M	427.27M	378.38M	290.41M
EBITDA	252.83M	276.26M	230.65M	215.55M	199.46M	231.67M
Net Income	133.03M	145.29M	121.30M	121.97M	113.16M	136.04M
Balance Sheet
Total Assets	1.82B	1.85B	1.46B	1.36B	1.22B	1.11B
Cash, Cash Equivalents and Short-Term Investments	128.67M	149.63M	175.91M	177.38M	172.79M	181.89M
Total Debt	325.62M	307.01M	120.11M	96.86M	95.37M	116.22M
Total Liabilities	750.28M	805.12M	545.81M	521.17M	498.84M	454.28M
Stockholders Equity	1.07B	1.04B	900.30M	839.33M	724.93M	620.97M
Cash Flow
Free Cash Flow	96.89M	134.97M	77.60M	45.41M	79.13M	81.23M
Operating Cash Flow	193.48M	204.22M	118.64M	98.98M	126.29M	110.22M
Investing Cash Flow	-133.80M	-428.69M	-121.87M	-54.83M	-51.21M	339.52M
Financing Cash Flow	-77.75M	138.59M	-2.56M	-34.76M	-91.69M	-349.89M

Virbac SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 362.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Positive. The current price of 362 is above the 20-day moving average (MA) of 328.35, above the 50-day MA of 326.50, and above the 200-day MA of 319.16, indicating a bullish trend. The MACD of 10.23 indicates Negative momentum. The RSI at 74.72 is Negative, neither overbought nor oversold. The STOCH value of 98.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VIRP.

Virbac SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	―	$108.25B	12.02	8.39%	4.45%	-9.82%	119.10%
VIRP	―	€3.04B	22.85	12.92%	0.40%	6.97%	-5.59%
VETO	―	€924.81M	15.37	10.80%	1.14%	-0.95%	27.67%
IPN	―	€9.41B	21.11	10.82%	1.17%	9.57%	-34.30%
BOI	―	€490.52M	25.10	5.22%	4.32%	4.80%	-18.25%
MEDCL	―	€1.19B	-57.86	―	―	181.43%	28.76%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%